Genentech Inc file suit Food Drug Administration U.S. District Court District Columbia unresolved issue relate genetically engineer human growth hormone. At issue Genentech whether Eli Lilly Co's ELI> recombinant human growth hormone recombinant growth hormone drug. Both drug review FDA. Since 1985 Genentech marketing Protropin recombinant human growth hormone treat abnormally short children. The biotechnology concern seven exclusive marketing Protropin grant orphan drug status FDA. Orphan drug special category drug treat rare diseases. Genentech suit seek clarification constitutes drug standard orphan Drug Act. It suggest "clarification" company develop orphan drug recover development cost period marketing exclusivity. It Lilly's growth hormone growth hormone differ slightly produce processes. Reuter 